Cours suspendu

Communiqués Forte Biosciences, Inc.

Actions

FBRX

US34962G2084

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
76,99 ^USD	+0,03 %		+0,13 %	+182,32 %

27/08	Argenx SE (ENXTBR:ARGX) a finalisé l'acquisition de Forte Biosciences, Inc. (NasdaqCM:FBRX).	CI
27/08	Argenx finalise l'acquisition de Forte Biosciences	MT

Communiqués

11/08	Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX	BU
28/07	Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX	BU
10/07	Forte Biosciences, Inc. - FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 after Completion of 12-Week Treatment Period	AQ
09/07	FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period	BU
11/05	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
11/05	Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update	BU
09/04	Forte Biosciences Announces Pricing of $150 Million Public Offering	BU
08/04	Forte Biosciences Announces Proposed Public Offering	BU
31/03	Forte Biosciences, Inc. Announces 2025 Results and Provides Update	BU
17/03	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules	BU
04/03	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules	BU
09/02	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings	BU
22/12	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
24/11	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
17/11	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update	AQ
14/11	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update	BU
03/11	Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences	BU
06/10/25	Forte Biosciences Inc. Reports Inducement Grants Under Nasdaq Listing Rules	AQ
03/10/25	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules	BU
15/09/25	Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium	BU
14/08/25	Forte Biosciences, Inc. Announces Results and Provides Update	BU
25/06/25	Forte Biosciences Announces Pricing of $75 Million Public Offering	BU
24/06/25	Forte Biosciences Announces Proposed Public Offering	BU
23/06/25	Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study	BU
15/05/25	Forte Biosciences, Inc. Announces Results and Provides Update	BU